InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.39%
)
US TECH 100
19,184.40
(
1.19%
)
Dow Jones
39,112.16
(
-0.76%
)
Brent Oil
84.19
(
-1.27%
)
Bitcoin
61,930.99
(
2.77%
)
Post# of 252343
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ilpapa

Send PM Follow Ignore
Followers 6
Posts 1313
Boards Moderated 0
Alias Born 11/02/2003

ilpapa

Re: None

Monday, 11/19/2012 9:17:44 AM

Monday, November 19, 2012 9:17:44 AM

Post# of 252343
GlaxoSmithKline (GSK) announced that the U.S. Food and Drug Administration has approved Promacta for the treatment of thrombocytopenia, or low blood platelet counts, in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. There are limitations to the use of PROMACTA in patients suffering from chronic hepatitis C-associated thrombocytopenia, the company noted.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up